VIGOR canine osteosarcoma tumor, cell line and skin samples
VSV-IFNß-NIS is a recombinant oncolytic vesicular stomatitis virus (VSV) that is being evaluated clinically for the treatment of advanced malignancies. As with other cancer immunotherapies, identifying biomarkers of response will be critical to the clinical advancement of this treatment approach. . RNAseq analysis showed that virtually all the long-term responders had increased expression of a CD8 T-cell anchored immune gene cluster. We conclude that neoadjuvant VSV-IFNß-NIS has an excellent safety profile and may provide a survival benefit for dogs with osteosarcoma whose tumors are permissive for immune infiltration. Overall design: RNA-Seq of fresh frozen osteosarcoma tissues pre and post treatment with vesicular stomatitis virus (VSV)  as well as cell lines grown from tumors skin tissues from these samples.